An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Monika Vnuk and Matt Lane join Blackstone Life Sciences as Managing Directors
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Blackstone Life Sciences (BXLS) announced the hiring of Dr. Monika Vnuk and Matt Lane as Managing Directors in Cambridge. Dr. Vnuk, previously with Pfizer, brings extensive experience in worldwide business development, notably in the COVID-19 vaccine partnership with BioNTech. Matt Lane has over 20 years in life sciences advising, including significant tenure at Cowen Group. BXLS currently manages over $7 billion in assets and aims to leverage the new hires' expertise to enhance investment activities in biopharmaceuticals.
Positive
Dr. Monika Vnuk and Matt Lane join BXLS as Managing Directors, enhancing the firm's leadership.
Dr. Vnuk brings valuable experience from Pfizer, particularly in COVID-19 vaccine partnerships.
Matt Lane's extensive advisory background in life sciences will strengthen BXLS's investment strategies.
BXLS has over $7 billion in assets under management, indicating strong financial positioning.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Blackstone Life Sciences (“BXLS”), Blackstone’s life sciences business, announced today that Dr. Monika Vnuk and Matt Lane have joined BXLS as Managing Directors in the firm’s Cambridge office. Dr. Vnuk joins from Pfizer, where she served as Vice President of Worldwide Business Development, having recently led Pfizer’s partnership with BioNTech for their COVID-19 vaccine. Mr. Lane joins with more than 20 years of experience in advising life sciences companies, including more than 15 years at Cowen Group, a leading life sciences focused investment bank.
Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences said: “We are excited to welcome Monika and Matt to the team. Their collective expertise in complex deal structuring, and their networks in the biopharmaceutical sector will help us expand our investment activities as we seek to advance important medicines to patients.”
Before joining Blackstone Life Sciences, Dr. Vnuk spent nearly 15 years in leadership roles at Pfizer, including most recently as Vice President of Worldwide Business Development. In that role she led the negotiation of the successful partnership with BioNTech directed at the global co-development and distribution of COVID-19 vaccines. Before joining Pfizer, Dr. Vnuk worked in investment banking at Bank of America and at Oxford Bioscience Partners, a life sciences venture capital firm. Dr. Vnuk holds an MD degree from the Boston University School of Medicine and a B.A. from Boston University.
Prior to joining Blackstone Life Sciences, Mr. Lane was a Managing Director at Gilmartin Group LLC, a strategic advisory firm. Before joining Gilmartin, Mr. Lane spent more than 15 years with Cowen Group as a Managing Director where he focused on supporting life sciences companies at all stages of their development. Before working in finance, Mr. Lane served as Press Secretary to US Senator Judd Gregg. He received a B.A. from Amherst College.
In July 2020, BXLS raised the largest private life sciences fund to date and currently has more than $7 billion in assets under management.
About Blackstone Life Sciences
Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients’ lives. More information is provided at https://www.blackstone.com/our-businesses/life-sciences/.
